34 studies found for:    Open Studies | "Carcinoid Tumor"
Show Display Options
Rank Status Study
1 Recruiting Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Conditions: Metastatic Gastrointestinal Carcinoid Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Neuroendocrine Carcinoma of the Skin;   Regional Gastrointestinal Carcinoid Tumor;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: pazopanib hydrochloride;   Other: placebo;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
2 Recruiting Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Endometrial Papillary Serous Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Papillary Serous Carcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Alpha Cell Carcinoma;   Pancreatic Beta Islet Cell Adenoma;   Pancreatic Beta Islet Cell Carcinoma;   Pancreatic Delta Cell Adenoma;   Pancreatic Delta Cell Carcinoma;   Pancreatic G-cell Adenoma;   Pancreatic G-cell Carcinoma;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Regional Gastrointestinal Carcinoid Tumor;   Stage IIIA Endometrial Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Endometrial Carcinoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Endometrial Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma;   Uterine Carcinosarcoma
Interventions: Drug: temsirolimus;   Biological: bevacizumab
3 Recruiting Natural History of Familial Carcinoid Tumor
Condition: Carcinoid
Intervention:
4 Recruiting Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Condition: Carcinoid Tumor
Intervention: Drug: Ziv-aflibercept
5 Recruiting Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Conditions: Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Intervention: Drug: Cabozantinib
6 Recruiting A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Condition: Carcinoid Tumors
Interventions: Drug: Lanreotide;   Drug: Placebo (for sunitinib);   Drug: Sunitinib
7 Recruiting A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Conditions: Carcinoid Tumor of the Small Bowel;   Neuroendocrine Tumour
Interventions: Drug: Octreotide;   Drug: 177Lu-DOTA0-Tyr3-Octreotate
8 Not yet recruiting 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Conditions: Neuroendocrine;   Neuroendocrine Tumor;   Neuroendocrine Cancer;   Neuroendocrine Carcinoma;   Carcinoid;   Carcinoid Tumor;   Islet Cell Tumor;   Apudoma
Intervention: Drug: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
9 Unknown  An Investigation of Small Intestinal Carcinoid Carcinoma in Families
Condition: Carcinoid Carcinoma
Intervention:
10 Unknown  Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors
Condition: Carcinoid Neuroendocrine Cancer
Intervention:
11 Recruiting YF476 in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome
Condition: Carcinoid
Intervention: Drug: YF476
12 Unknown  RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid
Conditions: Pheochromocytoma;   Extra-Adrenal Paraganglioma;   Non-functioning Carcinoid
Intervention: Drug: RAD001
13 Recruiting Telotristat Etiprate for Carcinoid Syndrome Therapy
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo
14 Unknown  Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neuroblastoma;   Pheochromocytoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Radiation: yttrium Y 90-edotreotide
15 Recruiting TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo tablets
16 Recruiting Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Metastatic Cancer
Intervention: Drug: PVA microporous hydrospheres/doxorubicin hydrochloride
17 Recruiting Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Condition: Carcinoid Syndrome
Intervention: Drug: Telotristat etiprate tablets (250 mg)
18 Recruiting SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor
Intervention:
19 Recruiting RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
Conditions: Carcinoma;   Neuroendocrine;   Non Functioning Neuroendocrine Tumors/NET;   Non Syndromic Neuroendocrine Tumors/NET;   Carcinoids;   Non Functioning
Intervention: Drug: Everolimus
20 Available 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
Conditions: Carcinoid Tumors;   Islet Cell (Pancreatic NET);   Other Neuroendocrine Tumors
Intervention: Drug: 68Ga-DOTA TATE

Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results
Indicates status has not been verified in more than two years